SCHEMBL6322299

SCHEMBL6322299

CC(CO)NS(=O)(=O)c1ccc(-c2cccs2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 3/20 0.62
CA12 O43570 2/20 0.62
CA2 P00918 2/20 0.62
CA9 Q16790 2/20 0.62
CA1 P00915 1/20 0.62
CA14 Q9ULX7 1/20 0.62
TDO2 P48775 2/20 0.46
MMP12 P39900 1/20 0.45
ALDH1A1 P00352 2/20 0.44
IKBKB O14920 2/20 0.43
CHUK O15111 2/20 0.43
ADAMTS4 O75173 5/20 0.43
KAT6A Q92794 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
GHSR Q92847 1/20 0.41
MMP3 P08254 2/20 0.41
MMP13 P45452 2/20 0.41
MMP1 P03956 1/20 0.41
MMP7 P09237 1/20 0.41
MMP9 P14780 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6326378 0.80 ADAMTS4 (0.65) MMP2CA12CA2CA9CA1
SCHEMBL6326385 0.80 ADAMTS4 (0.65) MMP2CA12CA2CA9CA1
SCHEMBL4802253 0.76 CA12 (0.58) MMP2CA12CA2CA9CA1
SCHEMBL31310982 0.76 SMN1; SMN2 (0.67) MMP2CA12CA2CA9CA1
SCHEMBL31310984 0.76 SMN1; SMN2 (0.67) MMP2CA12CA2CA9CA1
SCHEMBL6407534 0.75 CA12 (0.45) MMP2CA12CA2CA9CA1
SCHEMBL16519484 0.75 CA2 (0.68) MMP2CA12CA2CA9CA1
SCHEMBL16519485 0.75 CA2 (0.68) MMP2CA12CA2CA9CA1
SCHEMBL4752500 0.75 CA2 (0.68) MMP2CA12CA2CA9CA1
SCHEMBL6324016 0.75 ADAMTS4 (0.53) CA12CA2CA9CA1TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors PHARMACIA CORPORATION 2005-01-20 US disclosed
US-6747027-B1 SELECTIVELY INHIBITS IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-13 OVER IN VITRO ACTIVITY OF HUMAN MATRIX METALLOPROTEASE-1 PHARMACIA CORPORATION 2004-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014840-A1 Thiol sulfonamide metalloprotease inhibitors MMP12, MMP13, MMP3 MMP2 26/4885CA12 248/4885CA2 492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.